

## Coronavirus research and innovation projects

### Outcome of HERA Incubator call for expressions of interest on coronavirus variants: 11 projects



On 7 April 2021, the European Commission launched [an emergency request for expressions of interest](#) – the first under [Horizon Europe](#) – for EU-funded research and innovation actions to fight the coronavirus and contribute to the Commission's overall action to prevent, mitigate and respond to the impact of coronavirus variants, in line with the new European bio-defence preparedness plan [HERA Incubator](#).

On 22 July 2021, the EC announced that **11 projects** were short-listed for funding, with **total funding of €120 million**.

The 11 projects involve **312** research teams from **40** countries

in Europe and beyond, which are addressing the four topics of the emergency request for expressions of interest:

- **Clinical trials for therapeutics and vaccines** to boost COVID-19 prevention and treatment and further inform public health policy and clinical management.
- **Cohorts united against COVID-19 variants of concern** supporting activities that are enabling or contributing to the development of large scale, COVID-19 cohorts and networks worldwide, including beyond Europe's borders, forging links with European initiatives as a global response to the pandemic.
- **FAIR and open data sharing in support to European preparedness** for COVID-19 and other infectious diseases, to further develop and integrate platforms for the sharing of relevant research resources
- **Research infrastructure services for rapid research responses** to COVID-19 and other infectious disease epidemics, to set up and provide access to a comprehensive portfolio of relevant services

### 11 Horizon Europe research projects on coronavirus variants short-listed for funding

| Acronym   | Title  | Lead partner                                  | Partners  |
|---|--|---|---|
| <b>VACCINES &amp; THERAPEUTIC CLINICAL TRIALS TO BOOST COVID-19 PREVENTION &amp; TREATMENT – EU funding: € 30 m</b> |  |   |   |
| <b>VERDI</b>  | SARS-coV2 variants Evaluation in pRegnancy and paeDiatrics cohorts                 | Fondazione Penta (IT)                         | 22 partners: BE, CH, DE, EL, FR, HT, IT, NL, NO, SI, TH, UK, US, ZA |
| <b>EuCARE</b>   | European Cohorts of Patients and Schools to Advance Response to Epidemics          | EuResist Network GEIE (IT)                    | 18 partners: BE, DE, GE, IL, IT, LT, NL, PT, SE, UK                 |
| <b>CoVICIS</b>  | EU-Africa concerted action on SAR-CoV-2 virus variant & immunological surveillance | Centre Hospitalier Universitaire Vaudois (CH) | 14 partners: CH, DE, ET, FR, IT, NL, ZA                             |

| Acronym  | Title   | Lead partner   | Partners   |
|--|---|--|--|
| <b>COHORTS UNITED AGAINST COVID-19 VARIANTS OF CONCERN – EU funding: € 57 million</b>  |   |  |  |
| <b>ECRAID-PRIME</b>  | European Clinical Research Alliance on Infectious Diseases - PRIMARY care adaptive platform trial for pandemics and Epidemics | Universitair Medisch Centrum Utrecht (NL)                                  | 4 partners: BE, FR, NL, UK   |
| <b>XVR011 Phase 2</b>  | ExeVir's XVR011, a best in class nanobody-based biology that broadly neutralizes SARS-COV-1 and SARS-COV-2                    | ExeVir Bio (BE)  | 5 partners: BE, DE, FR, IE   |
| <b>RBDCOV</b>  | RBD Dimer recombinant protein vaccine against SARSCoV2  | HIPRA Scientific (ES)  | 13 partners: BE, DE, ES, IT, TR, UK  |
| <b>EPIC-CROWN-2</b>  | Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2-VOC   | Fabentech (FR)   | 5 partners: DE, EL, ES, FR   |
| <b>iMPact</b>  | Novel, orally available immune modulator MP1032 with anti-SARS-CoV-2 and anti-cytokine activity                               | MetrioPharm AG (CH)  | 4 partners: AT, CH, DE, NL   |
| <b>COVend</b>  | Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19            | Johann Wolfgang Goethe Universitaet Frankfurt-am-Main (DE)                 | 18 partners: BE, CH, DE, ES, FI, FR, IE, IT, LT, NL, PT, RO, SI,   |
| Acronym  | Title   | Lead Partner   | Partners   |
| <b>FAIR AND OPEN DATA SHARING IN SUPPORT TO EUROPEAN PREPAREDNESS FOR COVID-19 AND OTHER INFECTIOUS DISEASES – Total EU funding: € 12 million</b>        |   |  |  |
| <b>BY-COVID</b>  | Beyond COVID  | Johann Wolfgang Goethe Universitaet Frankfurt-am-Main (DE)                 | 53 partners: AT, BE, CH, CZ, DE, DK, EE, EL, ES, FI, FR, HU, IT, LU, NL, NO, SE, SI, UK  |
| <b>RESEARCH INFRASTRUCTURE SERVICES FOR RAPID RESEARCH RESPONSES TO COVID-19 AND OTHER INFECTIOUS DISEASE EPIDEMICS – Total EU funding: € 21 million</b> |   |  |  |
| <b>ISIDORe</b>   | Integrated Services for Infectious Disease Outbreak Research  | ERINHA - European Research Infrastructure on Highly pathogenic Agents (BE) | 156 partners: AT, AU, BD, BE, BF, BG, CH, CZ, DE, DK, EL, ES, FI, FR, HU, IE, IL, IT, LV, ML, NC, NL, NO, PL, PT, RS, SE, SI, SK, SN, UK, ZA |

[Information on EC support for coronavirus-related research](#)

© European Union, 2021.

Reuse is authorised provided the source is acknowledged and the original meaning or message of the document are not distorted. The European Commission shall not be liable for any consequence stemming from the reuse. The reuse policy of the European Commission documents is implemented by Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39).

All images © European Union, unless otherwise stated. Image: © realstock1 #329119752, 2020. Source: stock.adobe.com